Analysts Lower Marex Group Price Target Amid Accounting Allegations and Revised Profit Outlook

AN

AnalystConsensusTarget

AnalystConsensusTarget

Not Invested

Based on Analyst Price Targets

Published

27 Apr 25

Updated

09 Dec 25

Views

224

n/a

n/a

AnalystConsensusTarget's Fair Value

n/a

1Y

30.6%

7D

0.9%

Loading

1Y

30.6%

7D

0.9%

You can edit this narrative until Dec 10 3:10 AM. Then, changes will post as Updates.

Author's Valuation

US$47.7119.2% undervalued

AnalystConsensusTarget Fair Value

Shared on 09 Dec 25

Fair value Decreased 2.62%

MRX: US Expansion Will Drive Future Upside Despite Pending Securities Lawsuits

Narrative Update on Marex Group Price Target Analysts have modestly reduced their averaged price target on Marex Group from approximately $49.00 to about $47.70. This reflects slightly weaker top line growth assumptions, partially offset by expectations for improved profit margins and a marginally lower future price to earnings multiple.

Shared on 25 Nov 25

Fair value Increased 2.80%

MRX: Diversified US Expansion Will Drive Recovery Despite Securities Lawsuit Risk

Analysts have raised their price target for Marex Group from $47.67 to $49.00, citing updated assumptions around profit margins and discount rates, which support a modestly higher valuation. What's in the News Marex Group has launched its structured products business in the United States, led by Scott Kerbel.

Shared on 06 Nov 25

MRX: Revenue Outlook Will Support Rebound Despite Ongoing Class Action Lawsuits

Analysts have made a minor upward adjustment to the price target for Marex Group, now set at $47.67. This change is based on slight improvements in the revenue growth outlook and a stable discount rate.

Shared on 23 Oct 25

Fair value Decreased 3.38%

Analysts have slightly lowered their price target for Marex Group from $49.33 to $47.67. This change reflects recent updates to the company’s growth and profitability outlook.

Shared on 08 Oct 25

Fair value Decreased 3.06%

Analysts have lowered their price target for Marex Group from $50.89 to $49.33, citing slightly reduced profit margin forecasts and modestly improved revenue growth projections. What's in the News NINGI Research disclosed a short position in Marex Group, alleging the company used opaque off-balance-sheet entities, fictitious transactions, and misleading disclosures to obscure losses and inflate profits (Periodical).

Shared on 30 Apr 25

Fair value Decreased 1.72%

AnalystConsensusTarget Fair Value

US$47.71

19.2% undervalued

Future estimation in

Growth p.a.

Growth p.a.

%

Decrease

Increase

Current revenue growth rate

-8.51%

Capital Markets revenue growth rate

0.25%

Risk Level (Discount Rate)

Our default considers factors like the company's size, volatility, profitablity and country of operation.

%

0

Decrease

Increase

Current discount rate

13.46%

Calculation

US$395.08m

Earnings '28

x

13.41x

PE Ratio '28

=

US$5.30b

Market Cap '28

US$5.30b

Market Cap '28

/

76.18m

No. shares '28

=

US$69.53

Share Price '28

US$69.53 Share Price '28

Discounted to 2025 @ 13.46% p.a.

=

US$47.60

Fair Value '25